联亚药业
(301569)
| 流通市值：24.65亿 | | | 总市值：188.13亿 |
| 流通股本：1.17亿 | | | 总股本：8.92亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 1,329,422,852.89 | 1,236,716,932.24 | - | 1,098,993,501.51 |
| 交易性金融资产 | 80,850,737.68 | 100,073,433.57 | - | 100,190,728.78 |
| 应收票据及应收账款 | 193,371,097.21 | 171,417,274.89 | - | 173,018,748.25 |
| 应收账款 | 193,371,097.21 | 171,417,274.89 | - | 173,018,748.25 |
| 预付款项 | 29,418,458.06 | 17,934,801.43 | - | 24,120,866.8 |
| 其他应收款合计 | 2,897,715.94 | 1,874,167.58 | - | 2,347,107.65 |
| 存货 | 220,507,420.61 | 219,634,111.23 | - | 214,550,869 |
| 其他流动资产 | 6,389,590.81 | 6,280,756.74 | - | 5,524,727.08 |
| 流动资产平衡项目 | 0 | 0 | - | 0 |
| 流动资产合计 | 1,862,857,873.2 | 1,753,931,477.68 | - | 1,618,746,549.07 |
| 非流动资产: | | | | |
| 固定资产 | 541,263,682.24 | 412,756,652.72 | - | 347,174,996.39 |
| 在建工程 | 48,189,958.37 | 180,430,648.37 | - | 246,831,348.66 |
| 无形资产 | 42,988,760.49 | 43,270,553.22 | - | 43,167,674.91 |
| 递延所得税资产 | 30,045,546.45 | 30,590,295.72 | - | 29,453,223.09 |
| 其他非流动资产 | 7,707,998.04 | 8,035,724.08 | - | 8,476,911 |
| 非流动资产平衡项目 | 0 | 0 | - | 0 |
| 非流动资产合计 | 670,195,945.59 | 675,083,874.11 | - | 675,104,154.05 |
| 资产平衡项目 | 0 | 0 | - | 0 |
| 资产总计 | 2,533,053,818.79 | 2,429,015,351.79 | 2,340,071,200 | 2,293,850,703.12 |
| 流动负债: | | | | |
| 应付票据及应付账款 | 9,538,259.68 | 14,698,441.81 | - | 13,022,990.3 |
| 应付账款 | 9,538,259.68 | 14,698,441.81 | - | 13,022,990.3 |
| 合同负债 | 9,062,589.16 | 9,520,218.87 | - | 11,898,522.58 |
| 应付职工薪酬 | 21,035,654.94 | 16,146,144.43 | - | 26,753,756.94 |
| 应交税费 | 27,072,347.56 | 23,372,090.62 | - | 27,186,562.15 |
| 其他应付款合计 | 72,534,331.01 | 70,020,933.04 | - | 87,780,532.67 |
| 流动负债平衡项目 | 0 | 0 | - | 0 |
| 流动负债合计 | 139,243,182.35 | 133,757,828.77 | - | 166,642,364.64 |
| 非流动负债: | | | | |
| 递延收益 | 2,569,400.96 | 2,591,939.57 | - | 2,637,016.79 |
| 其他非流动负债 | 110,112,550.02 | 112,068,454.63 | - | 114,576,363.66 |
| 非流动负债平衡项目 | 0 | 0 | - | 0 |
| 非流动负债合计 | 112,681,950.98 | 114,660,394.2 | - | 117,213,380.45 |
| 负债平衡项目 | 0 | 0 | - | 0 |
| 负债合计 | 251,925,133.33 | 248,418,222.97 | 252,144,300 | 283,855,745.09 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 757,857,528 | 757,857,528 | - | 757,857,528 |
| 资本公积 | 863,451,134.91 | 848,061,948.94 | - | 817,805,953.64 |
| 其他综合收益 | -1,336,735.8 | -1,097,292.05 | - | -415,778.59 |
| 盈余公积 | 68,067,942.56 | 68,067,942.56 | - | 68,067,942.56 |
| 未分配利润 | 593,088,815.79 | 507,707,001.37 | - | 366,679,312.42 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | - | 0 |
| 归属于母公司股东权益合计 | 2,281,128,685.46 | 2,180,597,128.82 | 2,087,926,800 | 2,009,994,958.03 |
| 股东权益平衡项目 | 0 | 0 | - | 0 |
| 股东权益合计 | 2,281,128,685.46 | 2,180,597,128.82 | - | 2,009,994,958.03 |
| 负债和股东权益合计 | 2,533,053,818.79 | 2,429,015,351.79 | - | 2,293,850,703.12 |
| 公告日期 | 2026-10-30 | 2026-09-17 | 2026-07-02 | 2026-06-12 |
| 审计意见(境内) | | | | 标准无保留意见 |